Chuanyong Mu

1.2k total citations · 1 hit paper
24 papers, 964 citations indexed

About

Chuanyong Mu is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chuanyong Mu has authored 24 papers receiving a total of 964 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Immunology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chuanyong Mu's work include Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (8 papers) and Immune Cell Function and Interaction (4 papers). Chuanyong Mu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (8 papers) and Immune Cell Function and Interaction (4 papers). Chuanyong Mu collaborates with scholars based in China and Canada. Chuanyong Mu's co-authors include Jian‐An Huang, Xueguang Zhang, Cheng Chen, Ying Chen, Yanbin Chen, Qiu‐Xia Qu, Yibei Zhu, Yu Shen, Xueqin Pang and Cheng Chen and has published in prestigious journals such as PLoS ONE, Cancer Research and Frontiers in Immunology.

In The Last Decade

Chuanyong Mu

20 papers receiving 951 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

2010 503 citations Chuanyong Mu, Jian‐An Huang et al. Medical Oncology profile →

Peers

Countries citing papers authored by Chuanyong Mu

Since Specialization

Citations

This map shows the geographic impact of Chuanyong Mu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chuanyong Mu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chuanyong Mu more than expected).

Fields of papers citing papers by Chuanyong Mu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chuanyong Mu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chuanyong Mu. The network helps show where Chuanyong Mu may publish in the future.

Co-authorship network of co-authors of Chuanyong Mu

This figure shows the co-authorship network connecting the top 25 collaborators of Chuanyong Mu. A scholar is included among the top collaborators of Chuanyong Mu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chuanyong Mu. Chuanyong Mu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MCAM interacts with integrin β1 to promote EGFR-TKI resistance in lung adenocarcinoma through the JAK3 signalling pathway 2025 ·Journal of Translational Medicine ·(unknown), Yuling Chen, Chang Li, (unknown), Min Jiao, Mengzhu Zhang, (unknown), Anqi Wang, Jianjun Li, Yuanyuan Zeng, Jianjie Zhu, Chuanyong Mu, Jian-An Huang, Zeyi Liu	1
2	B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer 2025 ·Frontiers in Immunology ·Yang Zhang, Yang Yang, Yuanyuan Zeng, Qiu‐Xia Qu, (unknown), Chuanyong Mu, Lei Wei, (unknown), (unknown), Lirong Gao, Zeyi Liu, (unknown), (unknown)	0
3	Study on the complications after implantation of different types of metal stents in rabbit trachea 2024 ·International Journal of Pediatric Otorhinolaryngology ·(unknown), (unknown), Jie Zhang, Xiaoxiao Li, (unknown), Chuanyong Mu, Junhong Jiang	0
4	Cryoablation for airway stenosis caused by malignant pulmonary epithelioid hemangioendothelioma: a case report 2024 ·AME Case Reports ·(unknown), (unknown), Yao Zhang, Chuanyong Mu	0
5	The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients 2024 ·Cancer Treatment and Research Communications ·Li Wang, (unknown), Yao Zhang, Chuanyong Mu	0
6	The mitochondrial protein YME1 Like 1 is important for non-small cell lung cancer cell growth 2023 ·International Journal of Biological Sciences ·(unknown), Chunyan He, Zhiwei Hu, Zhichao Wu, Hui Yin, Yuan-Yuan Liu, Chuanyong Mu, (unknown)	14
7	The sodium/myo-inositol co-transporter SLC5A3 promotes non-small cell lung cancer cell growth 2022 ·Cell Death and Disease ·(unknown), Chuanyong Mu, Zhichao Wu, Shu Pan, (unknown), Zhi-qing Zhang, Jun Zhao, (unknown)	13
8	Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer 2021 ·Annals of Translational Medicine ·Daxiong Zeng, (unknown), Chuanyong Mu, (unknown), (unknown), Jian‐An Huang, Jiayue Xu, Lin Shao, Bing Li, Haiyan Li, Bingsi Li, Jun Zhao, Junhong Jiang	22
9	Transformation of Two Cases of Lung Adenocarcinoma into Pulmonary Sarcomatoid Carcinoma following Treatment 2021 ·Canadian Respiratory Journal ·(unknown), (unknown), Junhong Jiang, Ziyi Liu, Chuanyong Mu	4
10	Abstract 2311: Cell-free DNA from bronchoalveolar lavage fluid (BALF) for the identification of lung cancer: A new medium of liquid biopsy 2020 ·Cancer Research ·Junhong Jiang, Chuanyong Mu, (unknown), Daxiong Zeng, Changguo Wang, Junyi Ye, Jiayue Xu, Jing Su, Han Han‐Zhang, Bingsi Li, Haiyan Li, Zhihong Zhang	2
11	TRIM37 targets AKT in the growth of lung cancer cells 2018 ·OncoTargets and Therapy ·Shumin Dong, Xueqin Pang, Haijun Sun, (unknown), Chuanyong Mu, (unknown)	19
12	A study on mother‐to‐fetus/infant transmission of influenza A(H7N9) virus: Two case reports and a review of literature 2018 ·The Clinical Respiratory Journal ·Jiajia Wang, (unknown), Chuanyong Mu, Cheng Chen, Lingchuan Guo, Liling Chen, Jian‐An Huang, Qiang Guo	6
13	The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients 2017 ·PLoS ONE ·(unknown), Yitong Zhu, Jiajia Wang, Daxiong Zeng, Chuanyong Mu, Yanbin Chen, Wei Lei, Yehan Zhu, (unknown)	26
14	Soluble CD40 in plasma and malignant pleural effusion with non‐small cell lung cancer: A potential marker of prognosis 2015 ·Chronic Diseases and Translational Medicine ·Chuanyong Mu, (unknown), Qiu‐Xia Qu, Cheng Chen, Jian‐An Huang	18
15	Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study 2012 ·Tumori Journal ·Yanbin Chen, Chuanyong Mu, Jian‐An Huang	196
16	Association between single nucleotide polymorphism of PD‐L1 gene and non‐small cell lung cancer susceptibility in a Chinese population 2012 ·Asia-Pacific Journal of Clinical Oncology ·Yanbin Chen, Chuanyong Mu, Cheng Chen, Jian‐An Huang	20
17	Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: A potential mechanism of immune escape 2011 ·Cancer Letters ·Cheng Chen, Qiu‐Xia Qu, Yu Shen, Chuanyong Mu, Yibei Zhu, Xueguang Zhang, Jian‐An Huang	76
18	High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation breakdown → 2010 ·Medical Oncology ·Chuanyong Mu, Jian‐An Huang, Ying Chen, Cheng Chen, Xueguang Zhang	503
19	[The Expression and Biological Significance of PD-L1 on Lung Cancer Cell Lines.]. 2009 ·PubMed ·Cheng Chen, Chuanyong Mu, Qiu‐Xia Qu, (unknown), Jing Sun, Xueguang Zhang, (unknown)	2
20	The expression and significance of the multidrug resistance-related proteins P-gp, MRP and LRP in human non-small cell lung cancer tissues 2007 ·The Chinese-German Journal of Clinical Oncology ·Yun Zuo, Jian-An Huang, Chuanyong Mu, Dong Shen	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact